Retrieval of Patient Information After Discontinuation
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in
Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies
ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC